Answers are grounded in this paper and cite their sources.
In patients with follow-up for up to six treatments with onabotulinumtoxinA, treatment-related AEs were reported in <2% of the safety population over the course of nearly 5 years. Our findings from MOBILITY provide further evidence that onabotulinumtoxinA treatment is safe for long-term use across a variety of therapeutic indications.
No takes yet. Share an insight, caveat, or question.
Wein et al. (2019) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: